Versor Investments LP Raises Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Versor Investments LP raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 62.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 56,055 shares of the company’s stock after purchasing an additional 21,626 shares during the period. Versor Investments LP’s holdings in Hims & Hers Health were worth $1,355,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Creative Planning grew its position in Hims & Hers Health by 18.1% in the 3rd quarter. Creative Planning now owns 25,925 shares of the company’s stock valued at $478,000 after acquiring an additional 3,979 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Hims & Hers Health in the third quarter valued at approximately $6,790,000. Diversify Advisory Services LLC grew its holdings in shares of Hims & Hers Health by 14.9% in the third quarter. Diversify Advisory Services LLC now owns 51,828 shares of the company’s stock valued at $955,000 after purchasing an additional 6,706 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new position in shares of Hims & Hers Health in the third quarter valued at approximately $604,000. Finally, QRG Capital Management Inc. increased its stake in Hims & Hers Health by 3.9% during the 3rd quarter. QRG Capital Management Inc. now owns 162,029 shares of the company’s stock worth $2,985,000 after buying an additional 6,077 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $24.07, for a total value of $174,724.13. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $4,659,976.07. The trade was a 3.61 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,097,578 shares of company stock valued at $38,080,320. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday. Truist Financial raised their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday. Leerink Partners lifted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday. Finally, Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and a consensus target price of $34.47.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $41.87 on Thursday. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The stock has a market cap of $9.15 billion, a P/E ratio of 95.15 and a beta of 1.35. The firm has a fifty day moving average price of $35.89 and a 200 day moving average price of $26.36.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.